This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
2w0j
From Proteopedia
| Line 20: | Line 20: | ||
==About this Structure== | ==About this Structure== | ||
| - | 2W0J is a | + | 2W0J is a 1 chain structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2W0J OCA]. |
==Reference== | ==Reference== | ||
| Line 42: | Line 42: | ||
[[Category: Transferase]] | [[Category: Transferase]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb 15 08:37:39 2009'' |
Revision as of 06:37, 15 February 2009
CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH NSC 109555, A SPECIFIC INHIBITOR
Template:ABSTRACT PUBMED 19177354
About this Structure
2W0J is a 1 chain structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
- Lountos GT, Tropea JE, Zhang D, Jobson AG, Pommier Y, Shoemaker RH, Waugh DS. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci. 2009 Jan;18(1):92-100. PMID:19177354 doi:10.1002/pro.16
- Jobson AG, Cardellina JH 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R, Pommier Y. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol. 2007 Oct;72(4):876-84. Epub 2007 Jul 6. PMID:17616632 doi:10.1124/mol.107.035832
Page seeded by OCA on Sun Feb 15 08:37:39 2009
Categories: Homo sapiens | Non-specific serine/threonine protein kinase | Jobson, A G. | Lountos, G T. | Pommier, Y. | Shoemaker, R H. | Tropea, J E. | Waugh, D S. | Zhang, D. | Chk2 inhibitor | Kinase | Li-fraumeni syndrome | Nucleotide-binding | Oncology | Serine/threonine-protein kinase | Structure-assisted drug design | Transferase
